PAP - LIQUID BASED CYTOLOGY (LBC)

Pap – Liquid Based Cytology (LBC) is an advanced cervical cancer screening test used to detect precancerous changes, abnormal cervical cells, and early signs of cervical cancer. Compared with conventional Pap smear methods, Liquid Based Cytology provides improved sample quality and enhanced diagnostic accuracy.

The cervix is the lower part of the uterus that opens into the vagina. Changes in cervical cells often occur gradually over several years before cervical cancer develops. Early detection of these abnormalities allows timely treatment and significantly reduces the risk of cervical cancer progression.

During the test, cells are gently collected from the cervix using a specialized brush or spatula. Instead of being directly smeared onto a glass slide, the collected cells are preserved in a liquid medium. The sample is then processed in the laboratory to produce a clean, uniform slide for microscopic examination.

Liquid Based Cytology improves specimen preservation, reduces obscuring material such as blood and mucus, and allows for additional testing such as Human Papillomavirus (HPV) testing from the same sample when required.

Benefits of the Test

• Screens for cervical cancer and precancerous lesions
• Detects abnormal cervical cell changes early
• Improves sample quality compared to conventional Pap smears
• Reduces inadequate specimen rates
• Allows reflex HPV testing when indicated
• Supports routine women's preventive healthcare

Why Doctors Recommend This Test

Doctors commonly recommend Pap – Liquid Based Cytology for:

• Routine cervical cancer screening
• Detection of precancerous cervical lesions
• Evaluation of abnormal cervical findings
• HPV-related cervical disease assessment
• Follow-up of previous abnormal Pap results
• Women's preventive health examinations

Regular screening plays a vital role in preventing cervical cancer through early detection and treatment of abnormal cervical cells.

Preparation Before Test

For optimal results:

• Avoid sexual intercourse for 24–48 hours before the test if advised
• Avoid vaginal medications, creams, or douches before testing unless instructed otherwise
• Schedule the test when not menstruating if possible
• Follow specific instructions provided by your healthcare provider

The procedure is quick, safe, and usually completed within a few minutes.

Normal Reporting Time

Results are generally available within 3 to 7 working days, depending on laboratory processing and reporting protocols.

Who Should Take This Test?

• Women undergoing routine cervical cancer screening
• Individuals with previous abnormal Pap results
• Women with HPV infection
• Women advised by gynecologists for preventive screening
• Patients requiring cervical health evaluation

Screening recommendations may vary based on age, risk factors, and medical history.

Clinical Significance

The test may identify:

• Normal cervical cells
• Atypical squamous cells (ASC-US)
• Low-grade squamous intraepithelial lesions (LSIL)
• High-grade squamous intraepithelial lesions (HSIL)
• HPV-related cellular changes
• Cervical dysplasia
• Precancerous cervical lesions
• Cervical cancer

Early detection of abnormal cells enables timely intervention and improves long-term outcomes.